DUBLIN--(BUSINESS WIRE)--The "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis " report has been added to ResearchAndMarkets.com's offering.
Approximately 15.2 Million incidences of cancer were registered in 2015. This number is forecasted to reach an approximate value of 19.3 Million and 21.6 Million by 2025 and 2030, respectively.
Some of the conventional treatment options for the treatment of cancer are chemotherapy and radiation therapy. Even though these treatment options help in slowing down the progression of the disease, there is no option for the complete eradication of the disease. Moreover, these conventional therapies have numerous side-effects associated with them, such as hair loss, nausea and abnormal blood cell counts. These limitations and adverse effects of conventional therapies have therefore created a significant need for the treatment of cancer with therapies having lesser side effects and better efficacy. One such novel therapy is T-cell Immunotherapy which has shown great promise in the treatment of cancer even in the advanced stages.
According to report on Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis, T-cell Immunotherapy is a rapidly expanding field of oncology. This therapy is intended to overcome the challenge of getting the right type of T-cell to the target tumor. It makes use of patients own immune cells to fight cancer. These immune cells are obtained from the patient and genetically engineered before their use for the treatment.
Numerous researches are being performed across the globe to explore the potential of T-cell Immunotherapy for the treatment of different types of cancer. During these researches, T-cell Immunotherapies have demonstrated clinical successes on some accounts along with some critical issues on others. Overall, this therapy has emerged as one of the innovative and potent arm of the immunotherapeutic market.
Key Topics Covered:
1. Analyst View
2. Research Methodology
4. Global T-Cell Immunotherapy Market for Cancer
5. Global CAR T-Cell Immunotherapy Market for Cancer
6. Commercialized CAR T-Cell Immunotherapies for Cancer
7. Major Therapeutic Areas for T-Cell Immunotherapies
7.1 Hematological Malignancies
7.1.3 Multiple Myeloma
7.2 Solid Tumors
7.2.2 Bladder Cancer
7.2.3 Kidney Cancer
7.2.4 Ovarian Cancer
7.2.5 Breast Cancer
7.2.6 Lung Cancer
8. T-Cell Immunotherapy Pipeline Analysis
8.1 By Industry
8.1.1 By Vector
8.1.2 By Clinical Trial Phase
8.1.3 By Indication
8.1.4 By Technology
8.1.5 By Key Players
8.1.6 By Geography
8.2 By Research Collaborations
9. Market Opportunities
10. Key Player Analysis
10.1 Adaptimmune Therapeutics plc
10.2 Juno Therapeutics, Inc.
10.3 Gilead Sciences, Inc.
10.4 Novartis International AG
10.5 Tessa Therapeutics Pte Ltd.
10.6 Gradalis, Inc.
10.7 Immunovative Therapies, Ltd.
10.8 Iovance Biotherapeutics, Inc. (Formerly Lion Biotechnologies, Inc.)
10.9 Atara Biotherapeutics, Inc.
10.10 Celgene Corporation
10.11 Cellular Biomedicine Group
10.12 GlaxoSmithKline plc.
10.13 Immunocore Ltd.
10.14 Inovio Pharmaceuticals, Inc.
10.15 Cell Medica
For more information about this report visit https://www.researchandmarkets.com/research/bqw8qh/global_tcell?w=4